<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
The impact of the COVID-19 pandemic on antimicrobial usage: An international patient-level cohort study

Loading...
Thumbnail Image

Departments

School / College / Institute

Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit
Item type:Organizational Unit,
GRADUATE SCHOOL OF HEALTH SCIENCES
Upper Org Unit
Item type:Organizational Unit,

Program

Organization Authors

Co-Authors

Farzana, Refath

Harbarth, Stephan Jurgen

Yu, Ly-Mee

Carretto, Edoardo

Moore, Catrin E.

Feasey, Nicholas Alexander

Gales, Ana C.

Galal, Ushma

Yong, Dongeun

Yusuf, Md Abdullah

Date

Language

Embargo Status

Yes

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Background: This study aimed to evaluate the trends in antimicrobial prescription during the first 1.5 years of COVID-19 pandemic. Methods: This was an observational, retrospective cohort study using patient-level data from Bangladesh, Brazil, India, Italy, Malawi, Nigeria, South Korea, Switzerland and Turkey from patients with pneumonia and/or acute respiratory distress syndrome and/or sepsis, regardless of COVID-19 positivity, who were admitted to critical care units or COVID-19 specialized wards. The changes of antimicrobial prescription between pre-pandemic and pandemic were estimated using logistic or linear regression. Pandemic effects on month-wise antimicrobial usage were evaluated using interrupted time series analyses (ITSAs). Results: Antimicrobials for which prescriptions significantly increased during the pandemic were as follows: meropenem in Bangladesh (95% CI: 1.94-4.07) with increased prescribed daily dose (PDD) (95% CI: 1.17-1.58) and Turkey (95% CI: 1.09-1.58), moxifloxacin in Bangladesh (95% CI: 4.11-11.87) with increased days of therapy (DOT) (95% CI: 1.14-2.56), piperacillin/tazobactam in Italy (95% CI: 1.07-1.48) with increased DOT (95% CI: 1.01-1.25) and PDD (95% CI: 1.05-1.21) and azithromycin in Bangladesh (95% CI: 3.36-21.77) and Brazil (95% CI: 2.33-8.42). ITSA showed a significant drop in azithromycin usage in India (95% CI: -8.38 to -3.49â€...g/100 patients) and South Korea (95% CI: -2.83 to -1.89 g/100 patients) after WHO guidelines v1 release and increased meropenem usage (95% CI: 93.40-126.48 g/100 patients) and moxifloxacin (95% CI: 5.40-13.98 g/100 patients) in Bangladesh and sulfamethoxazole/trimethoprim in India (95% CI: 0.92-9.32 g/100 patients) following the Delta variant emergence. Conclusions: This study reinforces the importance of developing antimicrobial stewardship in the clinical settings during inter-pandemic periods. © 2025 The Author(s).

Source

Publisher

Oxford University Press

Citation

item.page.haspartof

Source

JAC-Antimicrobial resistance

item.page.ispartofseries

item.page.edition

DOI

10.1093/jacamr/dlaf037

item.page.datauri

item.page.link

Rights

CC BY (Attribution)

Copyrights Note

Creative Commons license

Except where otherwise noted, this item's license is described as CC BY (Attribution)

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators